Subchronic and chronic PCP treatment produces temporally distinct deficits in attentional set shifting and prepulse inhibition in rats
Authors:
- 23 April 2008
- journal article
- research article
- Published by Springer Nature in Psychopharmacology
- Vol. 198 (1) , 37-49
Abstract
Rationale We have previously demonstrated that subchronic (five daily administrations of 2.6 mg/kg PCP) and chronic intermittent administration of 2.6 mg/kg PCP to rats produces hypofrontality and other neurochemical changes akin to schizophrenia pathology (Cochran et al., Neuropsychopharmacology, 28:265–275, 2003). Objectives We sought to determine whether behavioral alterations related to discrete aspects of schizophrenia are also induced by these PCP treatment regimes. Materials and methods Following administration of vehicle or PCP according to the protocols described above, rats were assessed for attentional set shifting ability, prepulse inhibition (PPI), or social interaction and the locomotor response to a challenge dose of amphetamine. Results Ability to shift attentional set was impaired 72 h after the last PCP administration following the subchronic and chronic intermittent treatment regimes. PPI was disrupted after each acute administration of PCP in animals under the subchronic treatment regime. However, PPI deficits were not sustained 72 h after the last of five daily administrations. In subchronic and chronic PCP treated animals, no change was found in social interaction behavior, and there was little change in baseline or amphetamine-stimulated locomotor activity, employed as an indicator of dopaminergic hyperfunction. Conclusions The temporally distinct behavioral effects of these PCP treatment regimes suggest that PPI deficits relate directly to acute NMDA receptor antagonism, whereas the more enduring set shifting deficits relate to the longer term consequences of NMDA receptor blockade. Therefore, these subchronic and chronic PCP treatment regimes produce hypofrontality (Cochran et al., Neuropsychopharmacology, 28:265–275, 2003) and associated prefrontal cortex-dependent deficits in behavioral flexibility which mirror core deficits in schizophrenia.Keywords
This publication has 108 references indexed in Scilit:
- Rule shift under long-term PCP challenge in ratsBehavioural Brain Research, 2006
- The atypical antipsychotic drug clozapine enhances chronic PCP-induced regulation of prefrontal cortex 5-HT2A receptorsNeuropharmacology, 2004
- Beyond the K‐hole: a 3‐year longitudinal investigation of the cognitive and subjective effects of ketamine in recreational users who have substantially reduced their use of the drugAddiction, 2004
- Acute and delayed effects of phencyclidine upon mRNA levels of markers of glutamatergic and GABAergic neurotransmitter function in the rat brainSynapse, 2002
- Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophreniaNature Neuroscience, 2002
- Cortical regulation of subcortical dopamine systems and its possible relevance to schizophreniaJournal of Neural Transmission, 1993
- Extra-dimensional versus intra-dimensional set shifting performance following frontal lobe excisions, temporal lobe excisions or amygdalo-hippocampectomy in manNeuropsychologia, 1991
- Glucose Metabolic Rate in Normals and Schizophrenics During the Continuous Performance Test Assessed by Positron Emission TomographyThe British Journal of Psychiatry, 1990
- Dramatic limbic and cortical effects mediated by high affinity PCP receptorsLife Sciences, 1987
- Partial improvement in negative schizophrenic symptoms after amphetaminePsychopharmacology, 1982